Jennie Olofsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennie Olofsson has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Anna Månberg
Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
8 shared publications - Peter Nilsson
KTH Royal Institute of Technology
8 shared publications - Sofia Bergström
Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
5 shared publications - Ulf Kläppe
Department of Clinical Neuroscience, Karolinska Institutet
4 shared publications - Henrik Zetterberg
Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden
3 shared publications - Jamil Yousef
Affiliation Division of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 22 November 2024
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 26 (1-2) , 113-123
Cerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis
Objective: To evaluate the prognostic potential of neurofilament medium chain (NfM) in CSF from patients with ALS and explore its relationship with the extensively studied neurofilament light chain (NfL) and phosphorylated heavy chain (pNfH). Method: CSF levels of NfL, NfM, and pNfH were analyzed in 235 samples from patients with ALS, ALS mimics, and healthy controls in a well-characterized cohort from Karolinska ALS Clinical Research Center in Stockholm, Sweden. NfM levels were analyzed using an antibody-based suspension bead-array and NfL and pNfH levels were measured using ELISA. Clinical data, including ALS Revised Functional Rating Scale (ALSFRS-R), and survival outcomes were utilized for disease progression estimations. Result: Increased NfM levels were observed in patients with ALS compared with mimics and healthy controls. Similarly, higher NfM levels were found in fast compared with slow progressing patients for baseline and longitudinal progression when evaluating both total and subscores of ALSFRS-R. These findings were consistent with the results observed for NfL and pNfH. All three proteins, used individually as well as in combination, showed comparable performance when classifying fast vs slow progressing patients (AUCs 0.78-0.85). For all neurofilaments, higher survival probability was observed for patients with low CSF levels. Conclusion: Based on this cross-sectional study, the prognostic value provided by NfM aligns with the more established markers, NfL and pNfH. Additional investigations with independent cohorts and longitudinal studies are needed to further assess the potential added value of NfM.
- 22 November 2024
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 26 (1-2) , 113-123
Open AccessCerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis
Objective: To evaluate the prognostic potential of neurofilament medium chain (NfM) in CSF from patients with ALS and explore its relationship with the extensively studied neurofilament light chain (NfL) and phosphorylated heavy chain (pNfH). Method: CSF levels of NfL, NfM, and pNfH were analyzed in 235 samples from patients with ALS, ALS mimics, and healthy controls in a well-characterized cohort from Karolinska ALS Clinical Research Center in Stockholm, Sweden. NfM levels were analyzed using an antibody-based suspension bead-array and NfL and pNfH levels were measured using ELISA. Clinical data, including ALS Revised Functional Rating Scale (ALSFRS-R), and survival outcomes were utilized for disease progression estimations. Result: Increased NfM levels were observed in patients with ALS compared with mimics and healthy controls. Similarly, higher NfM levels were found in fast compared with slow progressing patients for baseline and longitudinal progression when evaluating both total and subscores of ALSFRS-R. These findings were consistent with the results observed for NfL and pNfH. All three proteins, used individually as well as in combination, showed comparable performance when classifying fast vs slow progressing patients (AUCs 0.78-0.85). For all neurofilaments, higher survival probability was observed for patients with low CSF levels. Conclusion: Based on this cross-sectional study, the prognostic value provided by NfM aligns with the more established markers, NfL and pNfH. Additional investigations with independent cohorts and longitudinal studies are needed to further assess the potential added value of NfM.
- Open Access
Cerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis
Objective To evaluate the prognostic potential of neurofilament medium chain (NfM) in CSF from patients with ALS and explore its relationship with the extensively studied neurofilament light chain (NfL) and phosphorylated heavy chain (pNfH). Method CSF levels of NfL, NfM, and pNfH were analysed in 235 samples from patients with ALS, ALS mimics, and healthy controls in a well-characterized cohort from Karolinska ALS Clinical Research Centre in Stockholm, Sweden. NfM levels were analysed using an antibody-based suspension bead-array and NfL and pNfH levels were measured using standard ELISA. Clinical data, including ALS Revised Functional Rating Scale (ALSFRS-R), and survival outcomes were utilized for disease progression estimations. Result Increased NfM levels were observed in patients with ALS compared with mimics and healthy controls, consistent with the results observed for NfL and pNfH. Similar to NfL and pNfH, significant associations of NfM levels with disease progression were found, with higher levels in fast progressors compared with slow progressors, both in total progression and the ALSFRS-R subscores. For all neurofilaments, higher survival probability was observed for patients with low CSF levels. Additionally, all three proteins showed similar predictive performance for disease progression rates (AUC 0.85-0.86). Although there was no statistical difference between the curves, combining them slightly improved the performance (AUC 0.86-0.87). Conclusion Based on this cross-sectional study, the prognostic value provided by NfM aligns with the more established markers, NfL and pNfH. However, additional investigations with independent cohorts and longitudinal studies are needed to further explore the potential added value of NfM.
Open AccessCerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis
Objective To evaluate the prognostic potential of neurofilament medium chain (NfM) in CSF from patients with ALS and explore its relationship with the extensively studied neurofilament light chain (NfL) and phosphorylated heavy chain (pNfH). Method CSF levels of NfL, NfM, and pNfH were analysed in 235 samples from patients with ALS, ALS mimics, and healthy controls in a well-characterized cohort from Karolinska ALS Clinical Research Centre in Stockholm, Sweden. NfM levels were analysed using an antibody-based suspension bead-array and NfL and pNfH levels were measured using standard ELISA. Clinical data, including ALS Revised Functional Rating Scale (ALSFRS-R), and survival outcomes were utilized for disease progression estimations. Result Increased NfM levels were observed in patients with ALS compared with mimics and healthy controls, consistent with the results observed for NfL and pNfH. Similar to NfL and pNfH, significant associations of NfM levels with disease progression were found, with higher levels in fast progressors compared with slow progressors, both in total progression and the ALSFRS-R subscores. For all neurofilaments, higher survival probability was observed for patients with low CSF levels. Additionally, all three proteins showed similar predictive performance for disease progression rates (AUC 0.85-0.86). Although there was no statistical difference between the curves, combining them slightly improved the performance (AUC 0.86-0.87). Conclusion Based on this cross-sectional study, the prognostic value provided by NfM aligns with the more established markers, NfL and pNfH. However, additional investigations with independent cohorts and longitudinal studies are needed to further explore the potential added value of NfM.
- Open Access
Addressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseases
Background Accurate diagnosis and monitoring of neurodegenerative diseases requires reliable biomarkers. Cerebrospinal fluid (CSF) proteins hold promise for reflecting brain pathology, yet their utility may be compromised by natural variability between individuals, weakening their association with disease and impacting their diagnostic accuracy. Method We measured the levels of 69 proteins in CSF from 499 individuals using an antibody-based suspension bead array technology. In this multi-disease cohort including participants with Alzheimer’s disease, behavioural variant frontotemporal dementia, primary progressive aphasias, amyotrophic lateral sclerosis, corticobasal syndrome, primary supranuclear palsy and healthy controls, we investigated inter-individual variability in CSF protein levels. Further, we explored protein profiles across the diseases, after adjusting for this variability using linear modelling. Results Correlation and PCA analysis on the measured CSF proteins revealed the presence of inter-individual variability in overall CSF levels of brain-derived proteins, which could not be explained by disease associations. Using linear modelling, we show that adjusting for median CSF levels of brain-derived proteins increases the diagnostic accuracy of many proteins, including those previously identified as altered in CSF in the context of neurodegenerative disorders. We further demonstrate a simplified approach for the adjustment using pairs of correlated proteins with opposite alteration in the diseases. With this approach, the proteins adjust for each other and further increase the biomarker performance through additive effect. Moreover, we find that many CSF proteins show similar alteration across the studied diseases, indicating that these proteins likely reflect shared processes. Conclusion CSF protein profiles are affected by inter-individual variability which partially hinders the diagnostic potential of CSF proteins. Thus, we propose that this variability should be accounted for in future studies. Further, we demonstrate high overlap in CSF protein patterns across neurodegenerative diseases, highlighting the need for multi-disease studies in order to identify biomarkers that are specific to or common between different diseases.
Open AccessAddressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseases
Background Accurate diagnosis and monitoring of neurodegenerative diseases requires reliable biomarkers. Cerebrospinal fluid (CSF) proteins hold promise for reflecting brain pathology, yet their utility may be compromised by natural variability between individuals, weakening their association with disease and impacting their diagnostic accuracy. Method We measured the levels of 69 proteins in CSF from 499 individuals using an antibody-based suspension bead array technology. In this multi-disease cohort including participants with Alzheimer’s disease, behavioural variant frontotemporal dementia, primary progressive aphasias, amyotrophic lateral sclerosis, corticobasal syndrome, primary supranuclear palsy and healthy controls, we investigated inter-individual variability in CSF protein levels. Further, we explored protein profiles across the diseases, after adjusting for this variability using linear modelling. Results Correlation and PCA analysis on the measured CSF proteins revealed the presence of inter-individual variability in overall CSF levels of brain-derived proteins, which could not be explained by disease associations. Using linear modelling, we show that adjusting for median CSF levels of brain-derived proteins increases the diagnostic accuracy of many proteins, including those previously identified as altered in CSF in the context of neurodegenerative disorders. We further demonstrate a simplified approach for the adjustment using pairs of correlated proteins with opposite alteration in the diseases. With this approach, the proteins adjust for each other and further increase the biomarker performance through additive effect. Moreover, we find that many CSF proteins show similar alteration across the studied diseases, indicating that these proteins likely reflect shared processes. Conclusion CSF protein profiles are affected by inter-individual variability which partially hinders the diagnostic potential of CSF proteins. Thus, we propose that this variability should be accounted for in future studies. Further, we demonstrate high overlap in CSF protein patterns across neurodegenerative diseases, highlighting the need for multi-disease studies in order to identify biomarkers that are specific to or common between different diseases.
- Open Access
- 27 September 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 291 (1) , 72-80
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS‐CoV‐2‐specific humoral and cellular immune responses more than 8 months post‐asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID‐19 patients. Possible protection against SARS‐CoV‐2 reinfection was analyzed by a weekly 3‐month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID‐19 patients and 96% (355/370) of HCW who were anti‐spike IgG positive at inclusion remained anti‐spike IgG positive at the 8‐month follow‐up. Circulating SARS‐CoV‐2‐specific memory T cell responses were detected in 88% (45/51) of COVID‐19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR‐confirmed SARS‐CoV‐2 infection was 1% (3/252) among anti‐spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti‐spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%–99.1%).Conclusions: The vast majority of anti‐spike IgG positive individuals remain anti‐spike IgG positive for at least 8 months regardless of initial COVID‐19 disease severity. The presence of anti‐spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID‐19.
- 27 September 2021
- Published by Wiley in Journal of Internal Medicine
- Vol. 291 (1) , 72-80
Open AccessRobust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID‐19
Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS‐CoV‐2‐specific humoral and cellular immune responses more than 8 months post‐asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID‐19 patients. Possible protection against SARS‐CoV‐2 reinfection was analyzed by a weekly 3‐month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID‐19 patients and 96% (355/370) of HCW who were anti‐spike IgG positive at inclusion remained anti‐spike IgG positive at the 8‐month follow‐up. Circulating SARS‐CoV‐2‐specific memory T cell responses were detected in 88% (45/51) of COVID‐19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR‐confirmed SARS‐CoV‐2 infection was 1% (3/252) among anti‐spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti‐spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%–99.1%).Conclusions: The vast majority of anti‐spike IgG positive individuals remain anti‐spike IgG positive for at least 8 months regardless of initial COVID‐19 disease severity. The presence of anti‐spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID‐19.
- Open Access
- 15 June 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (7) , 1456-1470
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Objective: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho‐tau in cerebrospinal fluid (CSF) is indicative of Alzheimer’s disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.Methods: We utilized an antibody‐based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Results: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP‐regulated phosphoprotein 21 (ARPP21), growth‐associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.Interpretation: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
- 15 June 2021
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 8 (7) , 1456-1470
Open AccessMulti‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Objective: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho‐tau in cerebrospinal fluid (CSF) is indicative of Alzheimer’s disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.Methods: We utilized an antibody‐based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Results: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP‐regulated phosphoprotein 21 (ARPP21), growth‐associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.Interpretation: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.
- 2 June 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (7) , 1308
Publisher Correction: Altered perivascular fibroblast activity precedes ALS disease onset
- 2 June 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (7) , 1308
Publisher Correction: Altered perivascular fibroblast activity precedes ALS disease onset
- 15 April 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (4) , 640-646
Altered perivascular fibroblast activity precedes ALS disease onset
Apart from well-defined factors in neuronal cells1, only a few reports consider that the variability of sporadic amyotrophic lateral sclerosis (ALS) progression can depend on less-defined contributions from glia2,3 and blood vessels4. In this study we use an expression-weighted cell-type enrichment method to infer cell activity in spinal cord samples from patients with sporadic ALS and mouse models of this disease. Here we report that patients with sporadic ALS present cell activity patterns consistent with two mouse models in which enrichments of vascular cell genes preceded microglial response. Notably, during the presymptomatic stage, perivascular fibroblast cells showed the strongest gene enrichments, and their marker proteins SPP1 and COL6A1 accumulated in enlarged perivascular spaces in patients with sporadic ALS. Moreover, in plasma of 574 patients with ALS from four independent cohorts, increased levels of SPP1 at disease diagnosis repeatedly predicted shorter survival with stronger effect than the established risk factors of bulbar onset or neurofilament levels in cerebrospinal fluid. We propose that the activity of the recently discovered perivascular fibroblast can predict survival of patients with ALS and provide a new conceptual framework to re-evaluate definitions of ALS etiology.
- 15 April 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (4) , 640-646
Altered perivascular fibroblast activity precedes ALS disease onset
Apart from well-defined factors in neuronal cells1, only a few reports consider that the variability of sporadic amyotrophic lateral sclerosis (ALS) progression can depend on less-defined contributions from glia2,3 and blood vessels4. In this study we use an expression-weighted cell-type enrichment method to infer cell activity in spinal cord samples from patients with sporadic ALS and mouse models of this disease. Here we report that patients with sporadic ALS present cell activity patterns consistent with two mouse models in which enrichments of vascular cell genes preceded microglial response. Notably, during the presymptomatic stage, perivascular fibroblast cells showed the strongest gene enrichments, and their marker proteins SPP1 and COL6A1 accumulated in enlarged perivascular spaces in patients with sporadic ALS. Moreover, in plasma of 574 patients with ALS from four independent cohorts, increased levels of SPP1 at disease diagnosis repeatedly predicted shorter survival with stronger effect than the established risk factors of bulbar onset or neurofilament levels in cerebrospinal fluid. We propose that the activity of the recently discovered perivascular fibroblast can predict survival of patients with ALS and provide a new conceptual framework to re-evaluate definitions of ALS etiology.
- Open Access
- 1 January 2021
- Published by Wiley in Clinical & Translational Immunology
- Vol. 10 (7) , e1312
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay
Objective: The COVID‐19 pandemic poses an immense need for accurate, sensitive and high‐throughput clinical tests, and serological assays are needed for both overarching epidemiological studies and evaluating vaccines. Here, we present the development and validation of a high‐throughput multiplex bead‐based serological assay.Methods: More than 100 representations of SARS‐CoV‐2 proteins were included for initial evaluation, including antigens produced in bacterial and mammalian hosts as well as synthetic peptides. The five best‐performing antigens, three representing the spike glycoprotein and two representing the nucleocapsid protein, were further evaluated for detection of IgG antibodies in samples from 331 COVID‐19 patients and convalescents, and in 2090 negative controls sampled before 2020.Results: Three antigens were finally selected, represented by a soluble trimeric form and the S1‐domain of the spike glycoprotein as well as by the C‐terminal domain of the nucleocapsid. The sensitivity for these three antigens individually was found to be 99.7%, 99.1% and 99.7%, and the specificity was found to be 98.1%, 98.7% and 95.7%. The best assay performance was although achieved when utilising two antigens in combination, enabling a sensitivity of up to 99.7% combined with a specificity of 100%. Requiring any two of the three antigens resulted in a sensitivity of 99.7% and a specificity of 99.4%.Conclusion: These observations demonstrate that a serological test based on a combination of several SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay.
- 1 January 2021
- Published by Wiley in Clinical & Translational Immunology
- Vol. 10 (7) , e1312
Open AccessSystematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay
Objective: The COVID‐19 pandemic poses an immense need for accurate, sensitive and high‐throughput clinical tests, and serological assays are needed for both overarching epidemiological studies and evaluating vaccines. Here, we present the development and validation of a high‐throughput multiplex bead‐based serological assay.Methods: More than 100 representations of SARS‐CoV‐2 proteins were included for initial evaluation, including antigens produced in bacterial and mammalian hosts as well as synthetic peptides. The five best‐performing antigens, three representing the spike glycoprotein and two representing the nucleocapsid protein, were further evaluated for detection of IgG antibodies in samples from 331 COVID‐19 patients and convalescents, and in 2090 negative controls sampled before 2020.Results: Three antigens were finally selected, represented by a soluble trimeric form and the S1‐domain of the spike glycoprotein as well as by the C‐terminal domain of the nucleocapsid. The sensitivity for these three antigens individually was found to be 99.7%, 99.1% and 99.7%, and the specificity was found to be 98.1%, 98.7% and 95.7%. The best assay performance was although achieved when utilising two antigens in combination, enabling a sensitivity of up to 99.7% combined with a specificity of 100%. Requiring any two of the three antigens resulted in a sensitivity of 99.7% and a specificity of 99.4%.Conclusion: These observations demonstrate that a serological test based on a combination of several SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay.